{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:25:00Z","timestamp":1791347100222,"version":"4.3.1"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1339,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,1]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>Domino liver transplantation (DLT) has emerged as a strategy for increasing the number of liver grafts available: morphologically normal livers from donors with metabolic diseases can be used for select recipients with hepatocellular carcinoma (usually outside the Milan criteria). Familial amyloidotic polyneuropathy (FAP) is the most common indication for DLT. When FAP patients are involved in DLT, the indications and outcomes are clear and good, although de novo FAP development within various periods of time has been described in DLT recipients of FAP livers. With the increasing need for organs, livers explanted from patients with rare metabolic diseases, such as primary hyperoxaluria (PH), acute intermittent porphyria (AIP), maple syrup urine disease (MSUD), and homozygous familial hypercholesterolemia (HFHC), are being used for DLT. However, insufficient data about the use of livers from patients with these rare metabolic diseases are available. In this review, we focus on the latter disorders. PH is not a good indication for DLT because recipients of PH livers develop hyperoxaluria and early acute renal failure. AIP also seems to be a debatable indication for DLT because of the rapid development of neurotoxicity in AIP liver recipients. However, the outcomes of DLT with HFHC and MSUD liver grafts (which include the risk of the de novo development of these genetic diseases) are promising. For rare metabolic liver diseases to be established as indications for DLT, more reports and studies are needed.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/lt.22443","type":"journal-article","created":{"date-parts":[[2011,10,10]],"date-time":"2011-10-10T19:27:39Z","timestamp":1318274859000},"page":"22-28","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":69,"title":["Domino Liver Transplantation"],"prefix":"10.1097","volume":"18","author":[{"given":"Irinel","family":"Popescu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona O.","family":"Dima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20250124","doi-asserted-by":"crossref","first-page":"759766","DOI":"10.1111\/j.1600-6143.2011.03477.x","article-title":"Operative risks of domino liver transplantation for the familial amyloid polyneuropathy liver donor and recipient: a double analysis.","volume":"11","author":"Tincani","year":"2011","journal-title":"Am J Transplant"},{"key":"R3-4-20250124","doi-asserted-by":"crossref","first-page":"350367","DOI":"10.1111\/j.1432-2277.2011.01225.x","article-title":"The European experience.","volume":"24","author":"Roels","year":"2011","journal-title":"Transpl Int"},{"key":"R4-4-20250124","doi-asserted-by":"crossref","first-page":"693699","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N Engl J Med"},{"key":"R5-4-20250124","first-page":"249254","article-title":"Domino as a bridge to definitive liver transplantation in a neonate.","volume":"6","author":"CasasMelley","year":"2002","journal-title":"Pediatr Transplant"},{"key":"R6-4-20250124","doi-asserted-by":"crossref","first-page":"467468","DOI":"10.1016\/S0041-1345(96)00206-0","article-title":"Sequential liver transplantation.","volume":"29","author":"Furtado","year":"1997","journal-title":"Transplant Proc"},{"key":"R7-4-20250124","doi-asserted-by":"crossref","first-page":"157158","DOI":"10.1002\/lt.500050204","article-title":"Maximum sharing of cadaver liver grafts composite split and domino liver transplants.","volume":"5","author":"Furtado","year":"1999","journal-title":"Liver Transpl Surg"},{"key":"R8-4-20250124","first-page":"644646","article-title":"Outcomes of domino liver transplantation: a single institutions experience.","volume":"42","author":"MarinGomez","year":"2010","journal-title":"Transplant Proc"},{"key":"R9-4-20250124","doi-asserted-by":"crossref","first-page":"270278","DOI":"10.1002\/lt.22210","article-title":"Domino versus deceased donor liver transplantation: association with early graft function and perioperative bleeding.","volume":"17","author":"Bispo","year":"2011","journal-title":"Liver Transpl"},{"key":"R10-4-20250124","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1056\/NEJM200506023522219","article-title":"Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation.","volume":"352","author":"Stangou","year":"2005","journal-title":"N Engl J Med"},{"key":"R11-4-20250124","doi-asserted-by":"crossref","first-page":"13861392","DOI":"10.1002\/lt.22174","article-title":"Risk of transmission of systemic transthyretin amyloidosis after domino liver transplantation.","volume":"16","author":"Llado","year":"2010","journal-title":"Liver Transpl"},{"key":"R12-4-20250124","first-page":"29983007","article-title":"Hereditary fibrinogen A alphachain amyloidosis: phenotypic characterization of a systemic disease and the role of liver transplantation.","volume":"115","author":"Stangou","year":"2010","journal-title":"Blood"},{"key":"R13-4-20250124","doi-asserted-by":"crossref","first-page":"13461348","DOI":"10.1097\/00007890-200105150-00030","article-title":"Domino hepatic transplantation using the liver from a patient with primary hyperoxaluria.","volume":"71","author":"Donckier","year":"2001","journal-title":"Transplantation"},{"key":"R14-4-20250124","doi-asserted-by":"crossref","first-page":"23242327","DOI":"10.1111\/j.1600-6143.2005.01014.x","article-title":"Severe course of primary hyperoxaluria and renal failure after domino hepatic transplantation.","volume":"5","author":"Franchello","year":"2005","journal-title":"Am J Transplant"},{"key":"R15-4-20250124","doi-asserted-by":"crossref","first-page":"25572560","DOI":"10.1093\/ndt\/gfi019","article-title":"Early renal failure after domino hepatic transplantation using the liver from a compound heterozygous patient with primary hyperoxaluria.","volume":"20","author":"Farese","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"R16-4-20250124","doi-asserted-by":"crossref","first-page":"782785","DOI":"10.1097\/TP.0b013e3181eefe1f","article-title":"Early renal failure after domino liver transplantation using organs from donors with primary hyperoxaluria type 1.","volume":"90","author":"Saner","year":"2010","journal-title":"Transplantation"},{"key":"R17-4-20250124","doi-asserted-by":"crossref","first-page":"571572","DOI":"10.7326\/0003-4819-154-8-201104190-00015","article-title":"Liver transplantation from donors with acute intermittent porphyria.","volume":"154","author":"Dowman","year":"2011","journal-title":"Ann Intern Med"},{"key":"R18-4-20250124","doi-asserted-by":"crossref","first-page":"876882","DOI":"10.1002\/lt.20744","article-title":"Domino liver transplantation in maple syrup urine disease.","volume":"12","author":"Khanna","year":"2006","journal-title":"Liver Transpl"},{"key":"R19-4-20250124","first-page":"539","article-title":"Domino liver transplantation (LT) in children and adults with maple syrup urine disease (MSUD).","volume":"8","author":"Mazariegos","year":"2008","journal-title":"Am J Transplant"},{"issue":"suppl 1","key":"R20-4-20250124","first-page":"S1","article-title":"Twentytwo month liver recipient with maple syrup urine disease donates liver to another toddler: a report on the worlds youngest domino pair.","volume":"16","author":"Mohan","year":"2010","journal-title":"Liver Transpl"},{"key":"R21-4-20250124","first-page":"6869","article-title":"Domino liver transplantation from children and adults with maple syrup urine disease.","volume":"10","author":"Gopasetty","year":"2010","journal-title":"Am J Transplant"},{"key":"R22-4-20250124","doi-asserted-by":"crossref","first-page":"13451350","DOI":"10.1097\/01.TP.0000093996.96158.44","article-title":"Homozygous familial hypercholesterolemia: specific indication for domino liver transplantation.","volume":"76","author":"Popescu","year":"2003","journal-title":"Transplantation"},{"key":"R23-4-20250124","doi-asserted-by":"crossref","first-page":"565570","DOI":"10.1111\/j.1399-0012.2008.00935.x","article-title":"Domino liver transplantation using a graft from a donor with familial hypercholesterolemia: sevenyr followup.","volume":"23","author":"Popescu","year":"2009","journal-title":"Clin Transplant"},{"key":"R24-4-20250124","doi-asserted-by":"crossref","first-page":"E30E33","DOI":"10.1111\/j.1399-3046.2009.01133.x","article-title":"Domino liver graft from a patient with homozygous familial hypercholesterolemia.","volume":"14","author":"Liu","year":"2010","journal-title":"Pediatr Transplant"},{"key":"R25-4-20250124","doi-asserted-by":"crossref","first-page":"366369","DOI":"10.1016\/S0272-6386(12)80624-X","article-title":"Molecular and clinical heterogeneity in primary hyperoxaluria type 1.","volume":"17","author":"Danpure","year":"1991","journal-title":"Am J Kidney Dis"},{"key":"R26-4-20250124","doi-asserted-by":"crossref","first-page":"177181","DOI":"10.1034\/j.1399-3046.2000.00107.x","article-title":"Longterm results of preemptive liver transplantation in primary hyperoxaluria type 1.","volume":"4","author":"Nolkemper","year":"2000","journal-title":"Pediatr Transplant"},{"key":"R27-4-20250124","doi-asserted-by":"crossref","first-page":"502511","DOI":"10.1093\/ndt\/6.7.502","article-title":"Toussaint. Combined liverkidney and isolated liver transplantations for primary hyperoxaluria type 1: the European experience. The European Study Group on Transplantation in Hyperoxaluria Type 1.","volume":"6","author":"Watts","year":"1991","journal-title":"Nephrol Dial Transplant"},{"key":"R28-4-20250124","doi-asserted-by":"crossref","first-page":"418422","DOI":"10.1016\/j.jpeds.2004.10.036","article-title":"Liver transplantation as definitive treatment for a factor V Leiden mutation.","volume":"146","author":"Dunn","year":"2005","journal-title":"J Pediatr"},{"key":"R29-4-20250124","doi-asserted-by":"crossref","first-page":"584593","DOI":"10.1016\/S1072-7515(99)00208-2","article-title":"Domino liver transplants for metabolic disorders: experience with familial amyloidotic polyneuropathy.","volume":"189","author":"Azoulay","year":"1999","journal-title":"J Am Coll Surg"},{"key":"R32-4-20250124","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.3109\/00207459408986065","article-title":"Maple syrup urine disease: clinical, EEG, and plasma amino acid correlations with a theoretical mechanism of acute neurotoxicity.","volume":"79","author":"Korein","year":"1994","journal-title":"Int J Neurosci"},{"key":"R33-4-20250124","first-page":"557564","article-title":"Elective liver transplantation for the treatment of classical maple syrup urine disease.","volume":"6","author":"Strauss","year":"2006","journal-title":"Am J Transplant"},{"key":"R34-4-20250124","first-page":"730734","article-title":"Midterm outcome of 2 cases with maple syrup urine disease: role of liver transplantation in the treatment in French.","volume":"1","author":"Netter","year":"1994","journal-title":"Arch Pediatr"},{"key":"R35-4-20250124","first-page":"A254","article-title":"Liver transplantation for maple syrup urine disease (MSUD) and methylmalonic acidopathy (MMA).","volume":"61","author":"Kaplan","year":"1997","journal-title":"Am J Hum Genet"},{"key":"R36-4-20250124","doi-asserted-by":"crossref","first-page":"627635","DOI":"10.1203\/00006450-200105000-00004","article-title":"Wholebody Lleucine oxidation in patients with variant form of maple syrup urine disease.","volume":"49","author":"Schadewaldt","year":"2001","journal-title":"Pediatr Res"},{"key":"R38-4-20250124","doi-asserted-by":"crossref","first-page":"24102411","DOI":"10.1056\/NEJM200512013532220","article-title":"Domino hepatic transplantation in maple syrup urine disease.","volume":"353","author":"Barshop","year":"2005","journal-title":"N Engl J Med"},{"key":"R39-4-20250124","doi-asserted-by":"crossref","first-page":"16581664","DOI":"10.1056\/NEJM198412273112603","article-title":"Liver transplantation to provide lowdensitylipoprotein receptors and lower plasma cholesterol in a child with homozygous familial hypercholesterolemia.","volume":"311","author":"Bilheimer","year":"1984","journal-title":"N Engl J Med"},{"key":"R41-4-20250124","doi-asserted-by":"crossref","first-page":"413422","DOI":"10.1097\/01.mol.0000137222.23784.2a","article-title":"Current management of severe homozygous hypercholesterolaemias.","volume":"15","author":"Naoumova","year":"2004","journal-title":"Curr Opin Lipidol"},{"issue":"suppl","key":"R42-4-20250124","first-page":"I158I163","article-title":"Portacaval shunt and liver transplantation in treatment of familial hypercholesterolemia.","volume":"9","author":"Bilheimer","year":"1989","journal-title":"Arteriosclerosis"},{"key":"R43-4-20250124","first-page":"601608","article-title":"Role of orthotopic liver transplant in the treatment of homozygous familial hypercholesterolemia in Spanish.","volume":"92","author":"Castilla Cabezas","year":"2000","journal-title":"Rev Esp Enferm Dig"},{"key":"R44-4-20250124","first-page":"630633","article-title":"Liver transplantation in patients with homozygotic familial hypercholesterolemia previously treated by endtoside portocaval shunt and ileal bypass.","volume":"35","author":"LopezSantamaria","year":"2000","journal-title":"J Pediatr Surg"},{"key":"R45-4-20250124","doi-asserted-by":"crossref","first-page":"276279","DOI":"10.1111\/j.1432-2277.2003.tb00299.x","article-title":"Livingdonor liver transplantation for homozygous familial hypercholesterolemia from a donor with heterozygous hypercholesterolemia.","volume":"16","author":"Shirahata","year":"2003","journal-title":"Transpl Int"},{"key":"R46-4-20250124","first-page":"13821383","article-title":"Heartliver transplantation in a patient with familial hypercholesterolaemia.","volume":"1","author":"Starzl","year":"1984","journal-title":"Lancet"},{"key":"R47-4-20250124","doi-asserted-by":"crossref","first-page":"E25E29","DOI":"10.1111\/j.1399-3046.2010.01383.x","article-title":"Preemptive liver transplantation in a child with familial hypercholesterolemia.","volume":"15","author":"Maiorana","year":"2011","journal-title":"Pediatr Transplant"},{"key":"R48-4-20250124","doi-asserted-by":"crossref","first-page":"123125","DOI":"10.1111\/j.1399-3046.2010.01458.x","article-title":"Liver transplantation as treatment for familial homozygous hypercholesterolemia: too early or too late.","volume":"15","author":"Malatack","year":"2011","journal-title":"Pediatr Transplant"},{"key":"R49-4-20250124","doi-asserted-by":"crossref","first-page":"269276","DOI":"10.1097\/MOT.0b013e3283399dbd","article-title":"Liver transplantation for inherited metabolic disorders of the liver.","volume":"15","author":"Moini","year":"2010","journal-title":"Curr Opin Organ Transplant"},{"key":"R50-4-20250124","doi-asserted-by":"crossref","first-page":"13781379","DOI":"10.1002\/lt.21497","article-title":"Venoplasty of hepatic venous outflow with a venous patch in domino liver transplantation.","volume":"14","author":"Liu","year":"2008","journal-title":"Liver Transpl"}],"container-title":["Liver Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.22443","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01445473-201201000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T17:12:46Z","timestamp":1737738766000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01445473-201201000-00004"}},"subtitle":["How Far Can We Push the Paradigm?"],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1002\/lt.22443","relation":{},"ISSN":["1527-6465"],"issn-type":[{"value":"1527-6465","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}